Literature DB >> 27809352

T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection.

Wenjing Yi1, Peixin Zhang1, Yan Liang1, Yun Zhou1, Huanjun Shen1, Chao Fan1, Jonathan P Moorman2, Zhi Q Yao2, Zhansheng Jia1, Ying Zhang1.   

Abstract

Hepatitis C virus (HCV) induces a high rate of chronic infection via dysregulation of host immunity. We have previously shown that T-cell immunoglobulin and mucin domain protein-3 (Tim-3) is up-regulated on monocyte/macrophages (M/Mφ) during chronic HCV infection; little is known, however, about the transcription factor that controls its expression in these cells. In this study, we investigated the role of transcription factor, T-box expressed in T cells (T-bet), in Tim-3 expression in M/Mφ in the setting of HCV infection. We demonstrate that T-bet is constitutively expressed in resting CD14+ M/Mφ in the peripheral blood. M/Mφ from chronically HCV-infected individuals exhibit a significant increase in T-bet expression that positively correlates with an increased level of Tim-3 expression. Up-regulation of T-bet is also observed in CD14+ M/Mφ incubated with HCV+ Huh7.5 cells, as well as in primary M/Mφ or monocytic THP-1 cells exposed to HCV core protein in vitro, which is reversible by blocking HCV core/gC1qR interactions. Moreover, the HCV core-induced up-regulation of T-bet and Tim-3 expression in M/Mφ can be abrogated by incubating the cells with SP600125 - an inhibitor for the c-Jun N-terminal kinase (JNK) signalling pathway. Importantly, silencing T-bet gene expression decreases Tim-3 expression and enhances interleukin-12 secretion as well as signal transducer and activator of transcription 1 phosphorylation. These data suggest that T-bet, induced by the HCV core/gC1qR interaction, enhances Tim-3 expression via the JNK pathway, leading to dampened M/Mφ function during HCV infection. These findings reveal a novel mechanism for Tim-3 regulation via T-bet during HCV infection, providing new targets to combat this global epidemic viral disease.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990hepatitis C viruszzm321990; T-bet; Tim-3; c-Jun N-terminal kinase pathway; monocyte/macrophages

Mesh:

Substances:

Year:  2016        PMID: 27809352      PMCID: PMC5290233          DOI: 10.1111/imm.12686

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

1.  T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells.

Authors:  Michael J Townsend; Amy S Weinmann; Jennifer L Matsuda; Rachelle Salomon; Peggy J Farnham; Christine A Biron; Laurent Gapin; Laurie H Glimcher
Journal:  Immunity       Date:  2004-04       Impact factor: 31.745

2.  Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9.

Authors:  Alaa Refaat; Yue Zhou; Shunsuke Suzuki; Ichiro Takasaki; Keiichi Koizumi; Shoji Yamaoka; Yoshiaki Tabuchi; Ikuo Saiki; Hiroaki Sakurai
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

3.  The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes.

Authors:  Richard G Jenner; Michael J Townsend; Ian Jackson; Kaiming Sun; Russell D Bouwman; Richard A Young; Laurie H Glimcher; Graham M Lord
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-05       Impact factor: 11.205

4.  Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection.

Authors:  Ying Zhang; Cheng J Ma; Lei Ni; Chun L Zhang; Xiao Y Wu; Uday Kumaraguru; Chuan F Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

Review 5.  Pathogenesis of hepatitis C-associated hepatocellular carcinoma.

Authors:  T Jake Liang; Theo Heller
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation.

Authors:  Angela Dolganiuc; Shilpa Oak; Karen Kodys; Douglas T Golenbock; Robert W Finberg; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells.

Authors:  Corey Smith; Diah Elhassen; Stephanie Gras; Katherine K Wynn; Vijayendra Dasari; Judy Tellam; Siok-Keen Tey; Sweera Rehan; Yu Chih Liu; Jamie Rossjohn; Scott R Burrows; Rajiv Khanna
Journal:  Blood       Date:  2012-08-31       Impact factor: 22.113

8.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

9.  Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection.

Authors:  Wei Wu; Yu Shi; Jie Li; Feng Chen; Zhi Chen; Min Zheng
Journal:  Virol J       Date:  2011-03-11       Impact factor: 4.099

10.  Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection.

Authors:  Ying Zhang; Cheng J Ma; Jia M Wang; Xiao J Ji; Xiao Y Wu; Zhan S Jia; Jonathan P Moorman; Zhi Q Yao
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

View more
  9 in total

1.  Porcine Circovirus Type 2 Suppresses IL-12p40 Induction via Capsid/gC1qR-Mediated MicroRNAs and Signalings.

Authors:  Qian Du; Xingchen Wu; Tongtong Wang; Xuefeng Yang; Zhenyu Wang; Yingying Niu; Xiaomin Zhao; Shan-Lu Liu; Dewen Tong; Yong Huang
Journal:  J Immunol       Date:  2018-06-01       Impact factor: 5.422

2.  Tim-3 exacerbates kidney ischaemia/reperfusion injury through the TLR-4/NF-κB signalling pathway and an NLR-C4 inflammasome activation.

Authors:  Y Guo; J Zhang; X Lai; M Chen; Y Guo
Journal:  Clin Exp Immunol       Date:  2018-05-07       Impact factor: 4.330

3.  Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis.

Authors:  Hualin Zhang; Yang Song; Huimin Yang; Zhiyan Liu; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

Review 4.  Mononuclear phagocyte system in hepatitis C virus infection.

Authors:  Yu Yang; Zheng-Kun Tu; Xing-Kai Liu; Ping Zhang
Journal:  World J Gastroenterol       Date:  2018-11-28       Impact factor: 5.742

5.  To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?

Authors:  Xiaoyun Wang; Joselyn Rojas-Quintero; Caroline A Owen
Journal:  Am J Respir Cell Mol Biol       Date:  2019-10       Impact factor: 7.748

Review 6.  The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies.

Authors:  Victoria C Brom; Christof Burger; Dieter C Wirtz; Frank A Schildberg
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

7.  miR-155 regulates pro- and anti-inflammatory cytokine expression in human monocytes during chronic hepatitis C virus infection.

Authors:  Yun Zhou; Peixin Zhang; Xuyang Zheng; Chuantao Ye; Mengyuan Li; Peiyu Bian; Chao Fan; Ying Zhang
Journal:  Ann Transl Med       Date:  2021-11

8.  Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19.

Authors:  Maojun You; Liang Chen; Dawei Zhang; Peng Zhao; Zhu Chen; En-Qiang Qin; Yanan Gao; Mark M Davis; Pengyuan Yang
Journal:  Nat Cell Biol       Date:  2021-06-09       Impact factor: 28.213

9.  Characteristics of Circulating CD4+ T Cell Subsets in Patients with Mycobacterium avium Complex Pulmonary Disease.

Authors:  Sun Ae Han; Yousang Ko; Sung Jae Shin; Byung Woo Jhun
Journal:  J Clin Med       Date:  2020-05-03       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.